421 related articles for article (PubMed ID: 21828122)
1. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Mrozik KM; Cheong CM; Hewett D; Chow AW; Blaschuk OW; Zannettino AC; Vandyke K
Br J Haematol; 2015 Nov; 171(3):387-99. PubMed ID: 26194766
[TBL] [Abstract][Full Text] [Related]
3. GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.
Cultrara CN; Kozuch SD; Ramasundaram P; Heller CJ; Shah S; Beck AE; Sabatino D; Zilberberg J
BMC Cancer; 2018 Dec; 18(1):1263. PubMed ID: 30563499
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
5. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
6. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.
Azab AK; Quang P; Azab F; Pitsillides C; Thompson B; Chonghaile T; Patton JT; Maiso P; Monrose V; Sacco A; Ngo HT; Flores LM; Lin CP; Magnani JL; Kung AL; Letai A; Carrasco R; Roccaro AM; Ghobrial IM
Blood; 2012 Feb; 119(6):1468-78. PubMed ID: 22096244
[TBL] [Abstract][Full Text] [Related]
7. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
8. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
10. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
11. Human osteoblasts express a repertoire of cadherins, which are critical for BMP-2-induced osteogenic differentiation.
Cheng SL; Lecanda F; Davidson MK; Warlow PM; Zhang SF; Zhang L; Suzuki S; St John T; Civitelli R
J Bone Miner Res; 1998 Apr; 13(4):633-44. PubMed ID: 9556063
[TBL] [Abstract][Full Text] [Related]
12. [Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment].
He NH; Zhou W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):475-481. PubMed ID: 37248571
[TBL] [Abstract][Full Text] [Related]
13. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
[TBL] [Abstract][Full Text] [Related]
14. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.
Raimondo S; Saieva L; Vicario E; Pucci M; Toscani D; Manno M; Raccosta S; Giuliani N; Alessandro R
J Hematol Oncol; 2019 Jan; 12(1):2. PubMed ID: 30621731
[TBL] [Abstract][Full Text] [Related]
18. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
[TBL] [Abstract][Full Text] [Related]
19. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]